Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms- |
Target |
Action stimulants, inhibitors |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), HLA-A2 inhibitors(HLA-A2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Myeloid Leukemia | Phase 1 | United States | 04 Nov 2020 | |
Acute Myeloid Leukemia | Phase 1 | Germany | 04 Nov 2020 | |
Acute Myeloid Leukemia | Phase 1 | United Kingdom | 04 Nov 2020 | |
Acute Myeloid Leukemia | Phase 1 | France | 04 Nov 2020 | |
Acute Myeloid Leukemia | Phase 1 | Australia | 04 Nov 2020 | |
Acute Myeloid Leukemia | Phase 1 | Spain | 04 Nov 2020 | |
Acute Myeloid Leukemia | Phase 1 | Taiwan Province | 04 Nov 2020 | |
Acute Myeloid Leukemia | Phase 1 | Denmark | 04 Nov 2020 | |
Acute Myeloid Leukemia | Phase 1 | Canada | 04 Nov 2020 | |
Acute Myeloid Leukemia | Phase 1 | Italy | 04 Nov 2020 |